Respiratory diseases specialist Verona Pharma (LSE: VRP) has announced the appointment of Richard Hennings to the company’s senior management team as commercial director.
Mr Hennings, who has more than a decade of strategic commercial biopharma leadership experience with companies including the US biotech giant Gilead (Nasdaq: GILD) and Anglo-Swedish pharma major AstraZeneca (LSE: AZN), will oversee Verona’s market access strategy and its increasing commercial focus.
"Richard brings extensive experience in commercial planning and launch preparations, as well as brand-building of innovative respiratory products in the USA and Europe"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze